A carregar...
Chemoimmunotherapy for Relapsed/Refractory and Progressive 17p13 Deleted Chronic Lymphocytic Leukemia (CLL) Combining Pentostatin, Alemtuzumab, and Low Dose Rituximab is Effective and Tolerable and Limits Loss of CD20 Expression by Circulating CLL Cells
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) patients with purine analogue refractory disease or TP53 dysfunction still have limited treatment options and poor survival. Alemtuzumab containing chemoimmunotherapy regimens can be effective but frequently cause serious infections. We r...
Na minha lista:
Publicado no: | Am J Hematol |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
2014
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4280857/ https://ncbi.nlm.nih.gov/pubmed/24723493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23737 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|